A phase II study of personalized selection of peptide vaccines combined with conventional chemo- or endocrine therapy for refractory breast cancer.

Authors:
  • UTU. Toh
    U. Toh
  • HOH. Otsuka
    H. Otsuka
  • NIN. Iwakuma
    N. Iwakuma
  • KSK. Shirouzu
    K. Shirouzu
  • EOE. Ogo
    E. Ogo
  • KIK. Itoh
    K. Itoh
  • MTM. Tanaka
    M. Tanaka
  • TFT. Fujii
    T. Fujii

Abstract
TPS173 Background: Immunotherapy using selected personalized peptide vaccines (PPV) has been reported to be effective for boosting anticancer immunity in many patients (pts) even in an advanced status. This study evaluate the anti-tumor immunologic effect and safety of PPV for pts with refractory breast cancer. Methods: Patient eligibility criteria: all patients had histologically confirmed measurable metastatic breast cancer and their HLA A molecules should be each of HLA-A2, A3, A11, A24, A26, A31 or A33. The following criteria were also required: age > 20 years, life expectancy of at least 3 months, ECOG performance status of 0 or 1, adequate vital organ function (WBC > 2,500/μ L; platelets > 80,000/μ L; serum creatinine < 1.5 mg/dL or creatinine clearance > 50 mL/min; AST and ALT < 2 times the upper limit of the institution's normal range; and total bilirubin < 2.5 mg/dL. All subjects provided written informed consent and the clinical protocol was approved by each institutional review board before patient enrollment. Treatment schedule:Pre- vaccination plasma was measured for their IgG levels reactive to each of the previously reported 31 candidate peptides followed by administration subcutaneously of the four peptides at maximum showing higher levels of IgG in order with schedule of every 1-2 week for a total of 6-24 doses. The concurrent conventional chemotherapy or endocrine therapy was available for the combination of PPV. Study design: This is an open-label, multicenter, single-arm, phase II study. The primary endpoint was anti-tumor immunologic effect and safety, and the secondary endpoints were clinical responses. The planned sample size was 60-80. Immune and clinical response assessment : Levels of IgG reactive to each of the 31 peptides in the pre- and post-treatment plasma at every 6 times of vaccination were measured using LUMNEX system. Clinical response was evaluated by RECIST criteria. Correlation between overall survival and the increased IgG levels was also investigated. No significant financial relationships to disclose.